Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.

Margot NA, Gibbs CS, Miller MD.

Antimicrob Agents Chemother. 2010 Jun;54(6):2345-53. doi: 10.1128/AAC.01784-09. Epub 2010 Mar 22.

2.

Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin.

Guo Q, Shen Y, Lee YS, Gibbs CS, Mrksich M, Tang WJ.

EMBO J. 2005 Sep 21;24(18):3190-201. Epub 2005 Sep 1.

3.

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, Miller MD, Fry J, Brosgart CL, Schiff ER, Xiong S.

J Viral Hepat. 2005 Jan;12(1):67-73.

PMID:
15655050
4.

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.

Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S.

Antimicrob Agents Chemother. 2004 Oct;48(10):3702-10.

5.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F.

Gastroenterology. 2004 Jun;126(7):1750-8.

PMID:
15188170
6.

Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.

Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E.

Nat Struct Mol Biol. 2004 May;11(5):469-74. Epub 2004 Apr 25.

PMID:
15107837
7.

Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery.

Carter WJ, Myles T, Gibbs CS, Leung LL, Huntington JA.

J Biol Chem. 2004 Jun 18;279(25):26387-94. Epub 2004 Apr 9.

8.

Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Shen Y, Zhukovskaya NL, Zimmer MI, Soelaiman S, Bergson P, Wang CR, Gibbs CS, Tang WJ.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3242-7. Epub 2004 Feb 20.

9.

Analysis of hepatitis B virus dynamics and its impact on antiviral development.

Tsiang M, Gibbs CS.

Methods Mol Med. 2004;96:361-77. No abstract available.

PMID:
14762282
10.

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trépo C, Zoulim F.

J Hepatol. 2003 Dec;39(6):1085-9.

PMID:
14642631
11.

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S.

J Virol. 2003 Nov;77(21):11833-41.

12.

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL, Xiong S; 437 and 438 Study Teams.

Hepatology. 2003 Jul;38(1):96-103.

PMID:
12829991
13.

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.

Le Guerhier F, Thermet A, Guerret S, Chevallier M, Jamard C, Gibbs CS, Trépo C, Cova L, Zoulim F.

J Hepatol. 2003 Mar;38(3):328-34.

PMID:
12586299
15.

Biochemical characterization of rhinovirus RNA-dependent RNA polymerase.

Hung M, Gibbs CS, Tsiang M.

Antiviral Res. 2002 Nov;56(2):99-114.

PMID:
12367717
16.

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.

Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S.

Hepatology. 2002 Aug;36(2):464-73.

PMID:
12143057
17.

Identification of critical residues on thrombin mediating its interaction with fibrin.

Hall SW, Gibbs CS, Leung LL.

Thromb Haemost. 2001 Dec;86(6):1466-74.

PMID:
11776315
18.

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T.

Lancet. 2001 Sep 1;358(9283):718-23.

PMID:
11551579
19.
20.

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, Lam S.

Hepatology. 2000 Aug;32(2):394-9.

PMID:
10915748
21.
22.

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.

Xiong X, Yang H, Westland CE, Zou R, Gibbs CS.

Hepatology. 2000 Jan;31(1):219-24.

PMID:
10613749
23.

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

Tsiang M, Rooney JF, Toole JJ, Gibbs CS.

Hepatology. 1999 Jun;29(6):1863-9.

PMID:
10347131
24.

Allosteric effects of a monoclonal antibody against thrombin exosite II

Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM.

Biochemistry. 1999 Feb 23;38(8):2610. No abstract available.

PMID:
10029715
25.

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.

Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS.

Hepatology. 1998 Dec;28(6):1669-73.

PMID:
9828233
26.

Allosteric effects of a monoclonal antibody against thrombin exosite II.

Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM.

Biochemistry. 1998 Oct 27;37(43):15057-65.

PMID:
9790668
27.

Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties.

Hall SW, Gibbs CS, Leung LL.

Cell Mol Life Sci. 1997 Sep;53(9):731-6. Review.

PMID:
9368669
28.

Modulation of thrombin's procoagulant and anticoagulant properties.

Leung LL, Gibbs CS.

Thromb Haemost. 1997 Jul;78(1):577-80. Review.

PMID:
9198219
29.
30.

Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.

Tsiang M, Paborsky LR, Li WX, Jain AK, Mao CT, Dunn KE, Lee DW, Matsumura SY, Matteucci MD, Coutré SE, Leung LL, Gibbs CS.

Biochemistry. 1996 Dec 24;35(51):16449-57.

PMID:
8987977
31.

A nickel chelate microtiter plate assay for six histidine-containing proteins.

Paborsky LR, Dunn KE, Gibbs CS, Dougherty JP.

Anal Biochem. 1996 Feb 1;234(1):60-5.

PMID:
8742083
32.

Conversion of thrombin into an anticoagulant by protein engineering.

Gibbs CS, Coutré SE, Tsiang M, Li WX, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, et al.

Nature. 1995 Nov 23;378(6555):413-6.

PMID:
7477382
33.

A peptide derived from a tissue factor loop region functions as a tissue factor--factor VIIa antagonist.

Paborsky LR, Law VS, Mao CT, Leung LL, Gibbs CS.

Biochemistry. 1995 Nov 21;34(46):15328-33.

PMID:
7578149
34.

Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics.

Tsiang M, Gibbs CS, Griffin LC, Dunn KE, Leung LL.

J Biol Chem. 1995 Aug 18;270(33):19370-6.

35.

Functional mapping of the surface residues of human thrombin.

Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS.

J Biol Chem. 1995 Jul 14;270(28):16854-63.

36.

Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis.

Gibbs CS, McCurdy SN, Leung LL, Paborsky LR.

Biochemistry. 1994 Nov 29;33(47):14003-10.

PMID:
7947809
37.

A template for the protein kinase family.

Taylor SS, Knighton DR, Zheng J, Sowadski JM, Gibbs CS, Zoller MJ.

Trends Biochem Sci. 1993 Mar;18(3):84-9. Review.

PMID:
8480367
41.

Sequence of a human glutamine synthetase cDNA.

Gibbs CS, Campbell KE, Wilson RH.

Nucleic Acids Res. 1987 Aug 11;15(15):6293. No abstract available.

42.

Ultrafiltration Experiments with the Viruses of Laryngotracheitis and Coryza of Chickens.

Gibbs CS.

J Bacteriol. 1935 Oct;30(4):411-7. No abstract available.

43.

THE ETIOLOGY OF EPIDEMIC COLDS IN CHICKENS.

Gibbs CS.

Science. 1935 Apr 5;81(2101):345-6. No abstract available.

PMID:
17807089
44.

The Desiccation and Preservation of Infectious Laryngotracheitis Virus.

Gibbs CS.

J Bacteriol. 1933 Mar;25(3):245-51. No abstract available.

Supplemental Content

Loading ...
Support Center